Current and Emerging Treatments for Myelodysplastic Syndromes: The 2021 Landscape

Friday, September 24, 2021 at 8:00 am – 9:00 am ET

Program Overview
Historically, there have been few effective treatment options for myelodysplastic syndromes (MDS), creating a critical unmet need for therapies. New agents approved in 2020 represent the first new options for MDS in the last several years. Additional novel agents are on the horizon which hold promise to impact the current treatment paradigm. Join us for this event and learn where we are today which may impact your practice in the near future.

Target Audience
This educational activity is designed for hematologist/oncologists, nurses, pharmacists, and other health care providers who provide care to patients with MDS.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

Identify MDS subtypes that correlate specific molecular mutations with targeted treatment plans
Utilize a conceptual framework for risk-adapted therapy for low- and high-risk MDS, to select optimal treatment approaches
Discuss options for relapsed/refractory lower-risk MDS and investigational new agents in lower-risk MDS with patients and families

Faculty


Mikkael A. Sekeres, MD, MS Professor of Medicine Chief of the Division of Hematology Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine Miami, Florida	Amy E. DeZern, MD, MHS Associate Professor of Oncology and Medicine Department of Oncology Sidney Kimmel Comprehensive Cancer Center The Johns Hopkins School of Medicine Baltimore, Maryland

Agenda

5 minutes	Welcome and Overview
10 minutes	Therapeutic Importance of Cytogenetic and Molecular Testing in MDS
20 minutes	Choosing Optimal Therapeutic Strategies in Lower-Risk MDS Current conceptual framework for low-risk disease in 2021 New and revisited treatment options for patients with lower-risk in 2021
20 minutes	Choosing Optimal Therapeutic Strategies in Higher-Risk MDS Prognosis in higher-risk MDS: The unmet need in the treatment of higher-risk disease Options for newly-diagnosed patients with higher-risk MDS Investigational approaches for patients with higher-risk MDS
5 minutes	Key Points for Practice and Conclusions

Accreditation

	CME Credit MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
	CPE Credit MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-21-036-L01-P. Knowledge-based CPE activity. In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program. International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
	Nursing Credit MediCom Worldwide, Inc. is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-036-147

Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosures
Dr. Mikkael Sekeres has relevant financial relationships related to advisory activities from Bristol-Myers Squibb Company, Novartis AG, and Takeda Oncology.

Dr. Amy DeZern has relevant financial relationships related to advisory activities from AbbVie Inc., Bristol-Myers Squibb Company, and Novartis AG, as well as relevant financial relationships related to the development of educational materials from Taiho Pharmaceutical Co., Ltd.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee
Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer
Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Instructions for Participation and Credit
In order to participate in this activity*, you must be registered as an attendee at the MDS Virtual Congress 2021. You may register by clicking the button below.

*Not included in the main conference CME/CPD credit.

In order to receive credit, all participants must complete the self-assessment post-test and Activity Evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.

Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation. A link to complete this will be included at the end of the program as well as emailed to participants 24 hours following the event.

CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x110 or [email protected].

Provided by

Supported by educational grants from Bristol-Myers Squibb and Astex Pharmaceuticals, Inc.